Despite improvements in the therapeutic approaches for hematological malignancies in the
last decades, refractory disease still occurs, and cancer drug resistance still remains a major …

Systemic chemotherapy has been used as the first-line therapy for patients with
hematological malignancies. Despite the enormous progress in anti-tumor efficacy achieved …

Drug resistance remains a major problem in the treatment of cancer patients for both
conventional chemotherapeutic and novel biological agents. Intrinsic or acquired resistance …

Chemoresistance is one of the main problems in the therapy of cancer. There are a number
of different molecular mechanisms through which a cancer cell acquires resistance to a …

Development of drug resistance has considerably limited the efficacy of cancer treatments,
including chemotherapy and targeted therapies. Hence, understanding the molecular …

MicroRNAs (miRNAs) are small non-coding RNAs with a length of about 19–25 nt, which
can regulate various target genes and are thus involved in the regulation of a variety of …

Drug resistance is a major problem in the treatment of cancer patients. Resistance can
develop after prolonged cycles of chemotherapy or can be present intrinsically in the patient …

The most common cause of cancer relapse is drug resistance, acquired or intrinsic, which
strongly limits the efficacy of both conventional and new targeted chemotherapy. MicroRNAs …

Chemotherapy has been widely used in treatment of cancer, both as systemic therapy and
as part of local treatment. Unfortunately, many kinds of cancer are still refractory to …

Despite the development of numerous therapies, cancer remains an incurable disease due
to various factors, including drug resistance produced by cancer cells. MicroRNAs (miRNAs) …